Vitamin D as an adjuvant in multiple sclerosis: statistical success and clinical limitations

Various risk factors are involved in the pathogenesis of multiple sclerosis, with vitamin D deficiency being associated with an increased risk of MS since the 1970s. Disease-modifying therapies aim to influence the underlying immune process to reduce relapses and lesion development. Given the conflicting results of previous studies on the therapeutic role of vitamin D in established MS patients, a comprehensive re-evaluation is required.